Aridis Pharmaceuticals Inc (NASDAQ:ARDS)’s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $7.59 and last traded at $8.54, with a volume of 10634 shares. The stock had previously closed at $8.50.
Several research firms recently issued reports on ARDS. Maxim Group began coverage on Aridis Pharmaceuticals in a research note on Tuesday, October 2nd. They set a “buy” rating on the stock. Northcoast Research began coverage on Aridis Pharmaceuticals in a research note on Monday, September 10th. They set an “outperform” rating and a $40.00 target price on the stock. Zacks Investment Research raised Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Tuesday, November 13th. Cantor Fitzgerald reissued a “buy” rating and set a $25.00 target price on shares of Aridis Pharmaceuticals in a research note on Tuesday, November 13th. Finally, Northland Securities began coverage on Aridis Pharmaceuticals in a research note on Monday, September 10th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Aridis Pharmaceuticals currently has an average rating of “Buy” and an average target price of $25.40.
Aridis Pharmaceuticals (NASDAQ:ARDS) last issued its quarterly earnings results on Tuesday, November 13th. The company reported ($1.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.92). The business had revenue of $1.02 million during the quarter, compared to the consensus estimate of $0.33 million. On average, analysts expect that Aridis Pharmaceuticals Inc will post -3.05 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Aridis Pharmaceuticals (ARDS) Hits New 52-Week Low at $7.59” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/12/08/aridis-pharmaceuticals-ards-hits-new-52-week-low-at-7-59.html.
About Aridis Pharmaceuticals (NASDAQ:ARDS)
Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L.
Recommended Story: Why do corrections happen?
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.